BeyondSpring Inc. announced that Mr. Patrick Fabbio has been appointed to the company’s Board of Directors as an independent director. Mr. Fabbio was also appointed to the Board's Audit Committee and will serve as Chair of that committee. In addition, each of Dr. Nanxing He, Managing Partner of Shenzhen Sangel Venture Capital Co., Ltd, and Mr. Mulong Liu, Executive Director of two affiliates of Shenzhen Sangel Venture Capital Co., Ltd, resigned from the Board and the Audit Committee. Dr. Quanqi Song, a current independent Board member, was appointed to the Audit Committee. Mr. Fabbio has more than 20 years of financial leadership experience with both public and private life science and pharmaceutical companies. He currently serves as the Chief Financial Officer of Progenics Pharmaceuticals Inc., which he joined in November 2015. Previously, he was the Chief Financial Officer of ElectroCore LLP and Vice President, Finance for NPS Pharmaceuticals Inc.